User login
Rare Neurological Disease Special Report
The 5th annual Rare Neurological Disease Special Report covers a wide range of topics related to rare neurological diseases. Nearly 20 bylined articles include overviews of specific diseases, discussions of translational science, reports on trends in diagnosis and screening, advice on resources for health care professionals, snapshots of emerging therapies, and more. This year’s issue has a special focus on genetics and the potential for genetic therapy to transform the treatment of rare diseases.
The 5th annual Rare Neurological Disease Special Report covers a wide range of topics related to rare neurological diseases. Nearly 20 bylined articles include overviews of specific diseases, discussions of translational science, reports on trends in diagnosis and screening, advice on resources for health care professionals, snapshots of emerging therapies, and more. This year’s issue has a special focus on genetics and the potential for genetic therapy to transform the treatment of rare diseases.
The 5th annual Rare Neurological Disease Special Report covers a wide range of topics related to rare neurological diseases. Nearly 20 bylined articles include overviews of specific diseases, discussions of translational science, reports on trends in diagnosis and screening, advice on resources for health care professionals, snapshots of emerging therapies, and more. This year’s issue has a special focus on genetics and the potential for genetic therapy to transform the treatment of rare diseases.
Fundamentals of Gene Therapy: Addressing Gaps in Physician Education
Click here to read supplement.
Gene therapy is a contemporary therapeutic intervention with recent positive results and regulatory approvals either completed or expected in the next several years for various conditions. In this supplement, learn more about:
- Basic principles of gene therapy
- In vivo vs ex vivo methods of gene transfer
- Vector types
- Clinical Considerations
About the Author
Click here to read supplement.
Click here to read supplement.
Gene therapy is a contemporary therapeutic intervention with recent positive results and regulatory approvals either completed or expected in the next several years for various conditions. In this supplement, learn more about:
- Basic principles of gene therapy
- In vivo vs ex vivo methods of gene transfer
- Vector types
- Clinical Considerations
About the Author
Click here to read supplement.
Click here to read supplement.
Gene therapy is a contemporary therapeutic intervention with recent positive results and regulatory approvals either completed or expected in the next several years for various conditions. In this supplement, learn more about:
- Basic principles of gene therapy
- In vivo vs ex vivo methods of gene transfer
- Vector types
- Clinical Considerations
About the Author
Click here to read supplement.
Migraine Update: A Review of CGRP-targeted Therapies
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
Study Design, Population, and Key Outcomes of DECLARE-TIMI 58 Compared With Other Cardiovascular Outcomes Trials for Sodium-Glucose Cotransporter-2 Inhibitors
Click here to read the supplement
- The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
- The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
- Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.
Click here to read the supplement
About the Author:
Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York
Click here to read the supplement
- The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
- The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
- Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.
Click here to read the supplement
About the Author:
Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York
Click here to read the supplement
- The cardiovascular (CV) safety and efficacy of the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) dapagliflozin was evaluated in the DECLARE-TIMI 58 study.
- The study design and patient population of DECLARE-TIMI 58 differed from those of other CV outcomes trials of SGLT-2is (EMPA-REG OUTCOME and CANVAS)
- Key outcome results between the 3 CV outcomes trials of SGLT-2is may have been affected by variations in the study designs and patient populations, given that DECLARE-TIMI 58 evaluated a larger population of patients with type 2 diabetes (T2D) without prior CV events than the EMPA-REG OUTCOME or CANVAS studies, potentially allowing for a broader generalizability of the study results to patients with T2D in real-world clinical practice.
Click here to read the supplement
About the Author:
Bulent S. Atac, MD
Albert Einstein College of
Medicine and Montefiore Medical Center,
Bronx, New York
Best Practices: The Emerging Science of the Developing Infant Skin Microbiome
Click here to read the supplement.
Learn about the latest research on the development of the skin microbiome in infancy (including the neonatal period), the essential role of a healthy skin microbiome, and practical advice for patients.
Kimberly A. Capone, PhD
Head, Microbiome Platform
Emerging Science & Innovation, Research & Development
Johnson & Johnson Consumer Inc.
Skillman, NJ USA
Click here to read the supplement.
Learn about the latest research on the development of the skin microbiome in infancy (including the neonatal period), the essential role of a healthy skin microbiome, and practical advice for patients.
Kimberly A. Capone, PhD
Head, Microbiome Platform
Emerging Science & Innovation, Research & Development
Johnson & Johnson Consumer Inc.
Skillman, NJ USA
Click here to read the supplement.
Learn about the latest research on the development of the skin microbiome in infancy (including the neonatal period), the essential role of a healthy skin microbiome, and practical advice for patients.
Kimberly A. Capone, PhD
Head, Microbiome Platform
Emerging Science & Innovation, Research & Development
Johnson & Johnson Consumer Inc.
Skillman, NJ USA
2019 Directory of VA and DoD Facilities
Current Considerations for Recognizing and Treating Iron Deficiency Anemia in Women
Click here to read the supplement.
Iron deficiency anemia (IDA) is one of the most common causes of anemia in women, and affects women of all ages. In this supplement, you will read about:
- How to identify IDA in women
- How to treat IDA
- A patient case study
Click here to read the supplement.
Click here to read the supplement.
Iron deficiency anemia (IDA) is one of the most common causes of anemia in women, and affects women of all ages. In this supplement, you will read about:
- How to identify IDA in women
- How to treat IDA
- A patient case study
Click here to read the supplement.
Click here to read the supplement.
Iron deficiency anemia (IDA) is one of the most common causes of anemia in women, and affects women of all ages. In this supplement, you will read about:
- How to identify IDA in women
- How to treat IDA
- A patient case study
